Medicus Pharma (NASDAQ:MDCX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $27.00 price objective on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $23.50.

Medicus Pharma Stock Performance

NASDAQ:MDCX opened at $0.50 on Thursday. Medicus Pharma has a fifty-two week low of $0.37 and a fifty-two week high of $8.94. The company has a 50 day moving average price of $1.09 and a 200 day moving average price of $1.78. The stock has a market capitalization of $12.78 million, a P/E ratio of -0.23 and a beta of -1.58.

Institutional Trading of Medicus Pharma

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in shares of Medicus Pharma during the second quarter worth approximately $41,000. Osaic Holdings Inc. increased its stake in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the period. Brave Asset Management Inc. acquired a new position in shares of Medicus Pharma during the third quarter worth about $46,000. Wilmington Savings Fund Society FSB purchased a new position in Medicus Pharma during the third quarter worth about $59,000. Finally, HRT Financial LP acquired a new stake in Medicus Pharma in the fourth quarter valued at about $42,000.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.